Lilly's Taltz-Zepbound combination improves psoriatic arthritis outcomes at one year in Phase 3b trial
LLY•Eli Lilly said combining Taltz with Zepbound improved disease control, physical function, fatigue and metabolic health versus Taltz alone over one year in a Phase 3b trial. Adverse events were generally mild to moderate.
1. One-year trial findings
The combination of Taltz and Zepbound improved disease control compared with Taltz alone in adults with psoriatic arthritis and obesity, or overweight with weight-related conditions, in Eli Lilly’s Phase 3b TOGETHER-PsA trial. Physical function, fatigue and metabolic health also improved versus Taltz alone, while adverse events were generally mild to moderate.
2. Presentation and publication
The findings were presented at ACR Convergence 2026 and published simultaneously in Arthritis & Rheumatology.
